Evidence map›Paper›PMID 27095111›Full record

ArticleInternational journal of clinical oncology2016

KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance.

Yanying Wang, Jianxin Jiang, Qun Li, Hong Ma, Zengguang Xu, Yong Gao

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Cross-Species Upregulation ofCurrent issues in molecular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. TRIM28 in cancer and cancer therapy.Frontiers in genetics · 2024
    Review
  9. Article
  10. The SUMOylation and ubiquitination crosstalk in cancer.Journal of cancer research and clinical oncology · 2023
    Review
  11. Article
  12. Review
  13. TRIM proteins in hepatocellular carcinoma.Journal of biomedical science · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yanying WangDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Jianxin JiangDepartment of Neurosurgery, Taizhou People's Hospital, Taizhou, 225300, Jiangsu Province, China.
Qun LiDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Hong MaDepartment of Ultrasonography, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Zengguang XuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. zengguangxu2008@yeah.net.
Yong GaoDepartment of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. gaoyon@hotmail.com.
Shanghai East Hospital · CNTaizhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe transcriptional regulator in embryonic development, KAP1, has been proved could promote cell proliferation and metastatic progression in a variety of human cancers. However, the role of KAP1 in hepatocellular carcinoma (HCC) remains unclear. The purpose of this study is to investigate the relationship of KAP1 expression with the progression and prognosis of HCC.

methodsWe measured the expression level of KAP1 in both human hepatoma cell lines and HCC tissues obtained from HCC patients by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot. Furthermore, the effect of KAP1 expression on hepatoma cell proliferation was investigated through KAP1 knock-down strategy. Besides that, the correlation between KAP1 expression and HCC progression was analyzed.

resultsKAP1 overexpression was proved broadly existed in the human hepatoma cell lines. Furthermore, down-regulate the expression of KAP1 by specific siRNA could inhibit cell proliferation which was partly originated from the activation of p53 mediated signal pathway. Moreover, comparisons between the cancer tissues and noncancerous tissues proved the expression level of KAP1 was significant higher in tumor tissues obtained from HCC patients. In addition, KAP1 overexpression was significantly correlated with tumor size and tumor stage and also a predictor for poor prognosis of HCC patients.

conclusionOur results presented here demonstrate that KAP1 plays an important role in HCC and could be regarded as a valuable biomarker for tumor diagnosis and prognosis prediction, as well as a potential target for the treatment of HCC.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell ProliferationDisease ProgressionFemaleGene ExpressionHumansLiverLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisRepressor ProteinsSignal TransductionBiomarkers, TumorRepressor ProteinsTRIM28 protein, humanTripartite Motif-Containing Protein 28BiomarkerHepatocellular carcinomaKAP1Prognosis

Identifiers

PMID27095111
OpenAlexW2337195458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.